Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of “Moderate Buy” by Brokerages

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has earned an average rating of “Moderate Buy” from the eight ratings firms that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $55.38.

A number of analysts have weighed in on CLDX shares. Cantor Fitzgerald restated an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a report on Wednesday, January 29th. UBS Group started coverage on Celldex Therapeutics in a report on Thursday, February 13th. They set a “buy” rating and a $44.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a report on Friday, February 28th. Finally, The Goldman Sachs Group decreased their price objective on Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating for the company in a report on Monday, March 3rd.

Celldex Therapeutics Stock Up 3.3 %

Celldex Therapeutics stock opened at $21.17 on Thursday. The business has a fifty day moving average of $23.09 and a two-hundred day moving average of $28.11. The firm has a market cap of $1.41 billion, a P/E ratio of -8.24 and a beta of 1.76. Celldex Therapeutics has a twelve month low of $18.61 and a twelve month high of $47.50.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.02. The company had revenue of $1.18 million during the quarter, compared to analyst estimates of $1.25 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. Equities analysts expect that Celldex Therapeutics will post -2.48 earnings per share for the current year.

Hedge Funds Weigh In On Celldex Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CLDX. GSA Capital Partners LLP raised its stake in Celldex Therapeutics by 191.2% in the 3rd quarter. GSA Capital Partners LLP now owns 16,114 shares of the biopharmaceutical company’s stock worth $548,000 after acquiring an additional 10,581 shares during the last quarter. KBC Group NV raised its stake in Celldex Therapeutics by 31.2% in the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 495 shares during the last quarter. Jennison Associates LLC raised its stake in Celldex Therapeutics by 32.0% in the 3rd quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock worth $45,017,000 after acquiring an additional 321,325 shares during the last quarter. Intech Investment Management LLC purchased a new position in Celldex Therapeutics in the 3rd quarter worth $871,000. Finally, Charles Schwab Investment Management Inc. raised its stake in Celldex Therapeutics by 1.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 538,856 shares of the biopharmaceutical company’s stock worth $18,316,000 after acquiring an additional 8,413 shares during the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.